Toshiaki Makino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Toshiaki Makino has a total of 285 co-authors. Here are the top co-authors by number of shared publications:
- Kan’iChiro Ishiuchi
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
16 shared publications Hajime Mizukami
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, 467-8603, Japan
15 shared publications- Masaaki Minami
Department of Bacteriology, Graduate School of Medical Sciences Nagoya City University Nagoya Japan
10 shared publications Takao Namiki
Chiba University, Japan
10 shared publicationsTsukasa Fueki
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
9 shared publications- Misato Ota
Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-Dori, Mizuho-ku, Nagoya, Aichi, 467-8603, Japan; Kuki Sangyo Co., Ltd., 11 Onoe-cho, Yokkaichi-shi, Mie, 510-0059, Japan
7 shared publications
Latest Publications
- 20 January 2026
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 80 (2) , 301-312
Effect of Shin’iseihaito (Xinyiqingfeitang) on MUC5AC expression in cultured pulmonary epithelial cells and the role of its component gypsum
- 20 January 2026
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 80 (2) , 301-312
Effect of Shin’iseihaito (Xinyiqingfeitang) on MUC5AC expression in cultured pulmonary epithelial cells and the role of its component gypsum
- 23 November 2025
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 80 (1) , 222-229
Effect of pre- and postprandial administration of Maoto extract granules on the pharmacokinetics of ephedrine and pseudoephedrine in healthy adults
Kampo medicines are widely co-prescribed with Western drugs, yet package inserts typically recommend preprandial dosing. This convention can complicate co-medication schedules and may reduce adherence, while human pharmacokinetic (PK) evidence on meal-timing effects remains limited. We compared pre- versus postprandial administration of maoto to quantify effects on absorption rate and extent for ephedrine and pseudoephedrine. In a two-period, two-sequence crossover, eight healthy adults received ethical maoto extract granules (2.5 g) 30 min before or after a standardized meal. Plasma ephedrine and pseudoephedrine were measured by LC–MS/MS through 24 h. PK was characterized by non-compartmental analysis (NCA) and a pre-specified one-compartment absorption model. The absorption rate constant (ka) was the mechanistic primary endpoint; AUC quantified extent. Sensitivity (male-only; leave-one-out) and crossover diagnostics (sequence/period) were conducted, and model adequacy was compared by modified Akaike’s Information Criterion (AICc). Preprandial dosing yielded higher Cmax, shorter Tmax, and larger ka for both analytes, indicating faster absorption. In contrast, AUC0–24 h and model-based AUC∞ were similar between conditions, and ke did not differ, indicating unchanged extent and disposition. Sensitivity analyses supported these findings; no sequence or period effects were detected. AICc distributions were comparable between conditions. Meal timing primarily alters the absorption rate of ephedrine/pseudoephedrine from maoto without materially changing overall exposure. Preprandial dosing may be preferred when rapid onset is desired, whereas postprandial dosing remains reasonable when adherence and co-medication scheduling are prioritized. Graphical abstract
- 23 November 2025
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 80 (1) , 222-229
Effect of pre- and postprandial administration of Maoto extract granules on the pharmacokinetics of ephedrine and pseudoephedrine in healthy adults
Kampo medicines are widely co-prescribed with Western drugs, yet package inserts typically recommend preprandial dosing. This convention can complicate co-medication schedules and may reduce adherence, while human pharmacokinetic (PK) evidence on meal-timing effects remains limited. We compared pre- versus postprandial administration of maoto to quantify effects on absorption rate and extent for ephedrine and pseudoephedrine. In a two-period, two-sequence crossover, eight healthy adults received ethical maoto extract granules (2.5 g) 30 min before or after a standardized meal. Plasma ephedrine and pseudoephedrine were measured by LC–MS/MS through 24 h. PK was characterized by non-compartmental analysis (NCA) and a pre-specified one-compartment absorption model. The absorption rate constant (ka) was the mechanistic primary endpoint; AUC quantified extent. Sensitivity (male-only; leave-one-out) and crossover diagnostics (sequence/period) were conducted, and model adequacy was compared by modified Akaike’s Information Criterion (AICc). Preprandial dosing yielded higher Cmax, shorter Tmax, and larger ka for both analytes, indicating faster absorption. In contrast, AUC0–24 h and model-based AUC∞ were similar between conditions, and ke did not differ, indicating unchanged extent and disposition. Sensitivity analyses supported these findings; no sequence or period effects were detected. AICc distributions were comparable between conditions. Meal timing primarily alters the absorption rate of ephedrine/pseudoephedrine from maoto without materially changing overall exposure. Preprandial dosing may be preferred when rapid onset is desired, whereas postprandial dosing remains reasonable when adherence and co-medication scheduling are prioritized. Graphical abstract
- 30 October 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 356, 120838
Inducible effects of evodiamine on the uptake of glutamine in Caco-2 cells
- 30 October 2025
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 356, 120838
Inducible effects of evodiamine on the uptake of glutamine in Caco-2 cells
- 10 October 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (11) , 100180
Stereoisomerism at the 3-position of glycyrrhetinic acid affects pseudoaldosteronism-related toxicokinetics
- 10 October 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (11) , 100180
Stereoisomerism at the 3-position of glycyrrhetinic acid affects pseudoaldosteronism-related toxicokinetics
- 5 October 2025
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 79 (6) , 1372-1388
Interactions between turnover rate and bioactivity of atractylenolide III in Atractylodes macrocephala rhizome in the theory of crude drugs’ pairs and prescriptions in traditional Chinese and Japanese Kampo medicine
The dried rhizome of Atractylodes macrocephala Koidz. (AM) is widely utilized in traditional Chinese and Japanese Kampo medicine for its therapeutic effects including digestive improvement, spleen strengthening, and dampness reduction. Atractylenolide III (AIII), an anti-inflammatory and gastric-protective sesquiterpene of AM, serves as a critical chemical reference substance (CRS) of AM, essential for its pharmacological validation. However, its content in the decoction of traditional formula varied due to its chemical properties. This study aimed to investigate the impact of the combinations of AM and other crude drugs in traditional medicinal drug-pair theory by assessing the relationship of extracting conditions, phytochemical profiles, and the bioactivities of the decoctions prepared using various crude drug combinations. AM was decocted with the dried sclerotium of Wolfiporia cocos (WE), the dried root and rhizome of Glycyrrhiza uralensis (GU), the dried root of Panax ginseng (PG), the dried twig of Cinnamomum cassia (CC), or the dried rhizome of Zingiber officinale (ZO), respectively, with varying ratios. The extraction parameters investigated included the ratio of crude drugs-to-water, heating times, and pH of the decoction. The contents of AIII and other CRS were analyzed using HPLC. Bioactivities, including anti-inflammatory effects in RAW 264.7 cells, gastroprotective effects in gastric mucosal cells, and antioxidative effects in SH-SY5Y neuronal cells, were also evaluated. The best extracting yield of AIII from AM was achieved with the ratio of crude drugs to water 1:60 (w/v) for 30-90 min of heating time at pH 5. The combinations of crude drugs significantly affected AIII turnover rates, with the highest yield obtained from formulations containing 25% AM, particularly the Lingguizhugantang (ryokeijutsukanto, LGZGT) that contains AM, WE, GU, and CC. The combination of crude drugs enhanced pharmacological activities, with LGZGT notably improving gastric mucosal protection and anti-inflammatory effects. In contrast, Shenzhetang (jinchakuto, SZT) that contains AM, WE, GU, and ZO, exhibited notable anti-inflammatory effects attributed to increased 6-gingerol content despite a reduced AIII concentration. These findings provide critical insights into optimizing AM-based formulations in traditional Chinese or Japanese Kampo medicinal theory for improving clinical efficacies and standardized phytochemical quality control. Graphical abstract
- 5 October 2025
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 79 (6) , 1372-1388
Interactions between turnover rate and bioactivity of atractylenolide III in Atractylodes macrocephala rhizome in the theory of crude drugs’ pairs and prescriptions in traditional Chinese and Japanese Kampo medicine
The dried rhizome of Atractylodes macrocephala Koidz. (AM) is widely utilized in traditional Chinese and Japanese Kampo medicine for its therapeutic effects including digestive improvement, spleen strengthening, and dampness reduction. Atractylenolide III (AIII), an anti-inflammatory and gastric-protective sesquiterpene of AM, serves as a critical chemical reference substance (CRS) of AM, essential for its pharmacological validation. However, its content in the decoction of traditional formula varied due to its chemical properties. This study aimed to investigate the impact of the combinations of AM and other crude drugs in traditional medicinal drug-pair theory by assessing the relationship of extracting conditions, phytochemical profiles, and the bioactivities of the decoctions prepared using various crude drug combinations. AM was decocted with the dried sclerotium of Wolfiporia cocos (WE), the dried root and rhizome of Glycyrrhiza uralensis (GU), the dried root of Panax ginseng (PG), the dried twig of Cinnamomum cassia (CC), or the dried rhizome of Zingiber officinale (ZO), respectively, with varying ratios. The extraction parameters investigated included the ratio of crude drugs-to-water, heating times, and pH of the decoction. The contents of AIII and other CRS were analyzed using HPLC. Bioactivities, including anti-inflammatory effects in RAW 264.7 cells, gastroprotective effects in gastric mucosal cells, and antioxidative effects in SH-SY5Y neuronal cells, were also evaluated. The best extracting yield of AIII from AM was achieved with the ratio of crude drugs to water 1:60 (w/v) for 30-90 min of heating time at pH 5. The combinations of crude drugs significantly affected AIII turnover rates, with the highest yield obtained from formulations containing 25% AM, particularly the Lingguizhugantang (ryokeijutsukanto, LGZGT) that contains AM, WE, GU, and CC. The combination of crude drugs enhanced pharmacological activities, with LGZGT notably improving gastric mucosal protection and anti-inflammatory effects. In contrast, Shenzhetang (jinchakuto, SZT) that contains AM, WE, GU, and ZO, exhibited notable anti-inflammatory effects attributed to increased 6-gingerol content despite a reduced AIII concentration. These findings provide critical insights into optimizing AM-based formulations in traditional Chinese or Japanese Kampo medicinal theory for improving clinical efficacies and standardized phytochemical quality control. Graphical abstract
- Open Access
- 3 March 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (3) , e70156
Comparison of the Efficacy and Safety of Disease‐Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta‐Analysis
There are several disease‐modifying antirheumatic drugs currently available to treat rheumatoid arthritis (RA). However, the optimal combination therapy with methotrexate for treating RA remains unclear. We aimed to identify combination therapies with high‐efficacy and safety by employing the Bayesian method in a network meta‐analysis. We systematically searched PubMed, Embase, CENTRAL, Ichushi web, and PMDA review reports and application materials through October 2020, and found 86 randomized controlled trials. The primary efficacy outcome was the 50% improvement rate according to the American College of Rheumatology criteria (ACR50), and the primary safety outcome was the incidence of serious adverse events. We calculated odds ratios (ORs) and its 95% credible intervals (CrIs) between each treatment, and the surface under the cumulative ranking curve (SUCRA) score for each treatment to rank disease‐modifying antirheumatic drug combinations. Individually, most disease‐modifying antirheumatic drugs combined with methotrexate are more likely to achieve ACR50 than methotrexate monotherapy, with significant differences (p < 0.05), whereas the incidence of serious adverse events was not significantly different compared with methotrexate monotherapy (p > 0.05). Infliximab combined with methotrexate had the highest efficacy ranking (OR = 10.53, 95% CrI: [3.20, 42.87], SUCRA score: 0.884), and etanercept combined with methotrexate had the highest safety ranking (OR = 0.29, 95% CrI: [0.03, 2.04], SUCRA score: 0.893). Comprehensive cluster analysis revealed that the combination of etanercept, an Fc‐fusion protein targeting tumor necrosis factor α, with methotrexate demonstrated higher efficacy and safety. These findings could support the selection of combination therapies for the treatment of RA.
- 3 March 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (3) , e70156
Open AccessComparison of the Efficacy and Safety of Disease‐Modifying Antirheumatic Drugs Combination Therapies: A Systematic Review and Network Meta‐Analysis
There are several disease‐modifying antirheumatic drugs currently available to treat rheumatoid arthritis (RA). However, the optimal combination therapy with methotrexate for treating RA remains unclear. We aimed to identify combination therapies with high‐efficacy and safety by employing the Bayesian method in a network meta‐analysis. We systematically searched PubMed, Embase, CENTRAL, Ichushi web, and PMDA review reports and application materials through October 2020, and found 86 randomized controlled trials. The primary efficacy outcome was the 50% improvement rate according to the American College of Rheumatology criteria (ACR50), and the primary safety outcome was the incidence of serious adverse events. We calculated odds ratios (ORs) and its 95% credible intervals (CrIs) between each treatment, and the surface under the cumulative ranking curve (SUCRA) score for each treatment to rank disease‐modifying antirheumatic drug combinations. Individually, most disease‐modifying antirheumatic drugs combined with methotrexate are more likely to achieve ACR50 than methotrexate monotherapy, with significant differences (p < 0.05), whereas the incidence of serious adverse events was not significantly different compared with methotrexate monotherapy (p > 0.05). Infliximab combined with methotrexate had the highest efficacy ranking (OR = 10.53, 95% CrI: [3.20, 42.87], SUCRA score: 0.884), and etanercept combined with methotrexate had the highest safety ranking (OR = 0.29, 95% CrI: [0.03, 2.04], SUCRA score: 0.893). Comprehensive cluster analysis revealed that the combination of etanercept, an Fc‐fusion protein targeting tumor necrosis factor α, with methotrexate demonstrated higher efficacy and safety. These findings could support the selection of combination therapies for the treatment of RA.
- 16 September 2024
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (12) , 1407-1416
3-epi-18β-Glycyrrhetinic Acid or Its Glucuronide, the Metabolites of Glycyrrhizinic Acid with Individual Differences, Correlated with Diagnostic Marker for Licorice-Induced Pseudoaldosteronism in Humans
Licorice is a crude drug that is used in traditional Japanese Kampo medicine and is also used as a sweetener. Occasionally, it causes pseudoaldosteronism (PsA) as a side effect. The major symptoms include hypokalemia, hypertension, edema, and low plasma aldosterone levels. PsA might be caused by the metabolites of glycyrrhizinic acid (GL), a component of licorice. The development of PsA markedly varies among individuals; however, the factors that cause these individual differences remain unknown. In this study, 78 patients who consumed Kampo medicines containing licorice were enrolled, and their laboratory data, including serum potassium levels, plasma aldosterone concentrations (PAC), and the concentrations of GL metabolites in the residual blood and/or urine samples were evaluated. Of the 78 participants, 18β-glycyrrhetinic acid (GA), 3-epi-GA, 3-oxo-GA, 18β-glycyrrhetinyl-30-O-glucuronide (GA30G), and 3-epi-GA30G were detected in the serum samples of 65, 47, 63, 62, and 3 participants, respectively. Of the 29 urine samples collected, GA30G and 3-epi-GA30G were detected in 27 and 19 samples. 3-epi-GA30G is a newly found GL metabolite. Moreover, 3-epi-GA, 3-oxo-GA, and 3-epi-GA30G were identified in human samples for the first time. High individual differences were found in the appearances of 3-epi-GA in serum and 3-epi-GA30G in urine, and the concentrations of these metabolites were correlated with serum PsA markers. The inhibitory titers of 3-epi-GA, 3-oxo-GA, GA30G, and 3-epi-GA30G on human 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) were almost similar. These findings suggest that 3-epi-GA and/or 3-epi-GA30G are associated with individual differences in the development of PsA. Significance Statement In this study, we detected 3-epi-GA in human serum for the first time. We also identified 3-epi-GA30G as a novel GL metabolite in human urine. These GL metabolite levels showed correlations with markers of PsA. Additionally, there are individual differences in whether or not they appear in the serum/urine. In conclusion, 3-epi-GA/3-epi-GA30G correlates with individual differences in the development of PsA.
- 16 September 2024
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (12) , 1407-1416
3-epi-18β-Glycyrrhetinic Acid or Its Glucuronide, the Metabolites of Glycyrrhizinic Acid with Individual Differences, Correlated with Diagnostic Marker for Licorice-Induced Pseudoaldosteronism in Humans
Licorice is a crude drug that is used in traditional Japanese Kampo medicine and is also used as a sweetener. Occasionally, it causes pseudoaldosteronism (PsA) as a side effect. The major symptoms include hypokalemia, hypertension, edema, and low plasma aldosterone levels. PsA might be caused by the metabolites of glycyrrhizinic acid (GL), a component of licorice. The development of PsA markedly varies among individuals; however, the factors that cause these individual differences remain unknown. In this study, 78 patients who consumed Kampo medicines containing licorice were enrolled, and their laboratory data, including serum potassium levels, plasma aldosterone concentrations (PAC), and the concentrations of GL metabolites in the residual blood and/or urine samples were evaluated. Of the 78 participants, 18β-glycyrrhetinic acid (GA), 3-epi-GA, 3-oxo-GA, 18β-glycyrrhetinyl-30-O-glucuronide (GA30G), and 3-epi-GA30G were detected in the serum samples of 65, 47, 63, 62, and 3 participants, respectively. Of the 29 urine samples collected, GA30G and 3-epi-GA30G were detected in 27 and 19 samples. 3-epi-GA30G is a newly found GL metabolite. Moreover, 3-epi-GA, 3-oxo-GA, and 3-epi-GA30G were identified in human samples for the first time. High individual differences were found in the appearances of 3-epi-GA in serum and 3-epi-GA30G in urine, and the concentrations of these metabolites were correlated with serum PsA markers. The inhibitory titers of 3-epi-GA, 3-oxo-GA, GA30G, and 3-epi-GA30G on human 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) were almost similar. These findings suggest that 3-epi-GA and/or 3-epi-GA30G are associated with individual differences in the development of PsA. Significance Statement In this study, we detected 3-epi-GA in human serum for the first time. We also identified 3-epi-GA30G as a novel GL metabolite in human urine. These GL metabolite levels showed correlations with markers of PsA. Additionally, there are individual differences in whether or not they appear in the serum/urine. In conclusion, 3-epi-GA/3-epi-GA30G correlates with individual differences in the development of PsA.
- Open Access
Mineral crude drug mirabilite (Mangxiao) inhibits the occurrence of colorectal cancer by regulating the Lactobacillus–bile acid–intestinal farnesoid X receptor axis based on multiomics integration analysis
Mineral crude drug has revolutionized the treatment landscape in precision oncology niche that leads to the improvement in therapeutic efficiency on various tumor subtypes. Mangxiao (MX), a mineral crude drug in traditional Chinese medicine, has been used for treating gastrointestinal diseases for thousands of years. However, the action mechanisms are still ambiguous. Here, we attempt to explore inhibitory roles and associated pharmacological mechanisms of MX upon colorectal cancer (CRC) in APCMin/+ male mice by integrating metabolomics, 16S rDNA sequencing analyses, and metagenomic‐based microbiota analysis. We found that MX can significantly inhibit the occurrence of CRC through the regulation of the dysregulated gut microbe metabolism. Furthermore, the correlation analysis of metabolomes and 16S rDNA revealed that MX could restore the disorders of gut microbes by specifically enriching the abundance of Lactobacilli to improve bile acid metabolism, which further activated the farnesoid X receptor (FXR) in CRC mice, then the improvement of gut dysbiosis could inhibit the development of CRC. Collectively, our effort confirmed MX has the capacity to intervene the development of CRC and further discovered that it targets Lactobacillus–bile acid–intestinal FXR axis, which can be regarded as a candidate medicine for future drug discovery and development against CRC.
Open AccessMineral crude drug mirabilite (Mangxiao) inhibits the occurrence of colorectal cancer by regulating the Lactobacillus–bile acid–intestinal farnesoid X receptor axis based on multiomics integration analysis
Mineral crude drug has revolutionized the treatment landscape in precision oncology niche that leads to the improvement in therapeutic efficiency on various tumor subtypes. Mangxiao (MX), a mineral crude drug in traditional Chinese medicine, has been used for treating gastrointestinal diseases for thousands of years. However, the action mechanisms are still ambiguous. Here, we attempt to explore inhibitory roles and associated pharmacological mechanisms of MX upon colorectal cancer (CRC) in APCMin/+ male mice by integrating metabolomics, 16S rDNA sequencing analyses, and metagenomic‐based microbiota analysis. We found that MX can significantly inhibit the occurrence of CRC through the regulation of the dysregulated gut microbe metabolism. Furthermore, the correlation analysis of metabolomes and 16S rDNA revealed that MX could restore the disorders of gut microbes by specifically enriching the abundance of Lactobacilli to improve bile acid metabolism, which further activated the farnesoid X receptor (FXR) in CRC mice, then the improvement of gut dysbiosis could inhibit the development of CRC. Collectively, our effort confirmed MX has the capacity to intervene the development of CRC and further discovered that it targets Lactobacillus–bile acid–intestinal FXR axis, which can be regarded as a candidate medicine for future drug discovery and development against CRC.
- Open Access
- 3 April 2024
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 78 (3) , 805
Correction: Heating or ginger extract reduces the content of Pinellia ternata lectin in the raphides of Pinellia tuber
- 3 April 2024
- Published by Springer Nature in Journal of Natural Medicines
- Vol. 78 (3) , 805
Open AccessCorrection: Heating or ginger extract reduces the content of Pinellia ternata lectin in the raphides of Pinellia tuber